Carlsmed, Inc. (CARL)
NASDAQ:CARL
Want to see CARL full AI Analyst Report?
CARL Stock Chart & Stats
$10.98
--
Market closed
$10.98
--
Day’s Range― - ―
52-Week Range$8.50 - $17.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)112.67K
Market Cap
$267.23M
Enterprise Value$210.65M
Total Cash (Recent Filing)$97.02M
Total Debt (Recent Filing)$17.25M
Price to Earnings (P/E)―
Beta2.79
Next Earnings
Aug 27, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding27,184,933
10 Day Avg. Volume137,166
30 Day Avg. Volume112,675
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.78
Price to Sales (P/S)3.48
P/FCF Ratio-5.93
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue3.73
Enterprise Value/Gross Profit4.92
Enterprise Value/Ebitda-5.57
Forecast
1Y Price Target
$18.40Price Target Upside67.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.53
Revenue Forecast (FY)$72.83M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And ScalingRecord additions of new surgeons, expanded surgeon education programs, and reduced product lead times are expected to accelerate procedure utilization and enable scaled commercial deployments.
Product Pipeline ExpansionAccelerated commercialization of the Aprevo cervical device and planned launches including a bilateral posterior lumbar fusion indication and a personalized cervical plating system could meaningfully expand addressable revenue and diversify the product portfolio.
Reimbursement UpliftCMS created dedicated higher‑paying billing codes for surgeries using the Aprevo device, increasing facility reimbursement and supporting broader hospital adoption of the company's lumbar products.
Bears Say
Market Sentiment And Share PerformanceShares have lagged the market benchmark, reflecting weaker investor confidence that may continue to weigh on the stock's performance.
Pricing Pressure And Mix ShiftA higher mix of lower‑priced procedures as new products ramp may lower the average selling price per procedure and pressure per‑procedure revenue.
Regulatory Implementation RiskCMS declined the request to move Aprevo cases into existing higher‑paying billing categories, highlighting regulatory complexity that could delay or complicate straightforward reimbursement implementation.
Carlsmed, Inc. News
CARL FAQ
What was Carlsmed, Inc.’s price range in the past 12 months?
Carlsmed, Inc. lowest stock price was $8.50 and its highest was $17.19 in the past 12 months.
What is Carlsmed, Inc.’s market cap?
Carlsmed, Inc.’s market cap is $267.23M.
When is Carlsmed, Inc.’s upcoming earnings report date?
Carlsmed, Inc.’s upcoming earnings report date is Aug 27, 2026 which is in 105 days.
How were Carlsmed, Inc.’s earnings last quarter?
Carlsmed, Inc. released its earnings results on May 05, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.06.
Is Carlsmed, Inc. overvalued?
According to Wall Street analysts Carlsmed, Inc.’s price is currently Undervalued.
Does Carlsmed, Inc. pay dividends?
Carlsmed, Inc. does not currently pay dividends.
What is Carlsmed, Inc.’s EPS estimate?
Carlsmed, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Carlsmed, Inc. have?
Carlsmed, Inc. has 27,184,933 shares outstanding.
What happened to Carlsmed, Inc.’s price movement after its last earnings report?
Carlsmed, Inc. reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went up 10.314%.
Which hedge fund is a major shareholder of Carlsmed, Inc.?
Currently, no hedge funds are holding shares in CARL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Carlsmed, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.40 (67.58% Upside)
$18.40 (67.58% Upside)
Blogger Sentiment
Bullish
CARL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 23.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-61.82%
Trailing 12-Months
Asset Growth
105.36%
Trailing 12-Months
Company Description
Carlsmed, Inc.
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product includes aprevo, a medical platform that makes surgical plans and devices tailored to the precise medical situation of every individual patient. It provides New Technology Add-On Payment (NTAP) reimbursement. The company was incorporated in 2018 and is based in Carlsbad, California.
CARL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: robust top-line growth (Q1 revenue +58%), significant surgeon adoption (+60% surgeon users YoY), production efficiencies (lead time cut >30%, gross margin +220 bps), compelling peer‑reviewed clinical outcomes (74% reduction in two-year revisions), and constructive reimbursement developments (NTAP renewal and proposed favorable CMS coding). Offsetting these positives are rising operating expenses (+61% YoY), deeper GAAP losses and negative adjusted EBITDA, and higher cash burn from operations. The company raised full-year revenue guidance and expects operating leverage as revenue scales, while some policy items remain preliminary. On balance, the business appears to be in a growth-investment phase with improving unit economics and strong market validation but elevated near-term losses as it invests to scale.View all CARL earnings summariesCARL Stock 12 Month Forecast
Average Price Target
$18.40
▲(67.58% Upside)
Technical Analysis
Ownership Overview
54.76% Insiders
6.08% Mutual Funds
1.11% Other Institutional Investors
35.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---